Table 1 Eighteen-month changes with docosahexaenoic acid or placebo treatment by apolipoprotein E ε4 status on CSF DHA, Aβ42, Tau and p-Tau levels
From: The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease
DHA treated, APOE ɛ4 non-carriers (n = 4) | Placebo treated, APOE ɛ4 non-carriers (n = 4) | DHA treated, APOE ɛ4 carriers (n = 25) | Placebo treated, APOE ɛ4 carriers (n = 11) | |||||
|---|---|---|---|---|---|---|---|---|
Baseline | 18 months | Baseline | 18 months | Baseline | 18 months | Baseline | 18 months | |
DHA,a % by weight | 2.21 (0.44) | 3.71 (0.71) | 2.66 (0.81) | 1.95 (0.28) | 2.46 (0.59) | 3.38 (0.90) | 2.28 (0.6) | 2.18 (0.50) |
Aβ42, pg/ml | 208 (55) | 189 (51) | 190 (36) | 183 (36) | 150 (30) | 140 (30) | 151 (35) | 145 (33) |
Tau, pg/ml | 120 (110) | 121 (125) | 118 (42) | 129 (35) | 112 (53) | 108 (136) | 133 (94) | 126 (88) |
p-Tau,b pg/ml | 39 (43) | 40 (43) | 47 (23) | 53 (28) | 47 (18) | 44 (17) | 53 (37) | 51(33) |